Rune is currently a developmental company undergoing a Series B fundraise to complete development of its first product.

Upon completion of final formulation work and clinical strategy to launch, we will be applying for a FDA Orphan Drug Designation and Fast track ticket.

Once fully funded we can continue to develop our earlier phase products through to launch and subsequent commercialisation.

Rune is targeting standard terms of 5-10x initial investment within 5 years.